First trial restored under new initiative casts doubt on repeat bowel cancer surgery

May 13, 2014, British Medical Journal

A trial that remained unpublished for 20 years casts doubt on the survival benefit of repeat—'second look'—surgery for bowel cancer.

The trial is published in the online journal BMJ Open today. It is the first to be restored under the restoring invisible and abandoned (RIAT) initiative that allows third parties to publish previously abandoned studies when the original researchers or sponsors fail to do so.

The initiative was announced last year by editors of The BMJ and PLOS Medicine as a way to complete and correct the scientific record, so that doctors and patients have access to accurate information to make decisions about treatments.

On bmj.com today, Professor Tom Treasure and colleagues tell the story behind the trial and discuss what it means today.

The trial started in 1982 and examined the use of a tumour marker (carcinoembryonic antigen or CEA) to detect cancer recurrence early and prompt second look surgery. The researchers wanted to see whether this would result in better survival.

Nearly 1,500 patients who had already had surgery took part in the trial. Those with high CEA levels, suggesting their cancer had returned, were randomised to further surgery (active arm) or to continued review (control arm).

But the trial was stopped early in 1993 when it was found that there were more deaths in the active arm than the control arm.

Although there was a clear intention to publish the results, various factors led to the trial team breaking up and the data were thought to be irretrievably lost.

When the RIAT initiative was announced, Professor Tom Treasure at University College London and colleagues at the University of Sussex and Imperial College London had already retrieved the archived files and were in the process of analysing the data.

Spurred on by the initiative, their updated analysis confirms that there is no hint of a survival advantage associated with knowledge of the CEA.

They acknowledge that methods of detection, imaging, and surgical resection have changed over the intervening 20 years, but they do not believe that the findings can be readily discounted.

They say the new evidence "should fuel uncertainty about present day second look for colorectal in its various forms and hope that it will give some encouragement to undertake the randomised trials that are needed."

Explore further: Experts propose restoring invisible and abandoned trials 'to correct the scientific record'

Related Stories

Experts propose restoring invisible and abandoned trials 'to correct the scientific record'

June 13, 2013
Experts are today calling for all unpublished and misreported trials to be published or formally corrected within the next year to ensure doctors and patients rely on complete and accurate information to make decisions about ...

Follow-up tests improve colorectal cancer recurrence detection

January 14, 2014
Among patients who had undergone curative surgery for primary colorectal cancer, the screening methods of computed tomography and carcinoembryonic antigen each provided an improved rate of surgical treatment of cancer recurrence ...

New study could improve survival rate of colon cancer patients

March 6, 2014
A unique trial at Queen's University could improve the survival rate of patients with colon cancer. This is the first study to test if exercise can improve the cure rate of colon cancer and improve quality of life and physical ...

Unexpected results in cancer drug trial

April 8, 2014
Research from the University of Southampton has shown a drug, used in combination with chemotherapy to treat advanced colorectal cancer, is not effective in some settings, and indeed may result in more rapid cancer progression.

Radiotherapy after mastectomy benefits women with breast cancer in 1-3 lymph nodes

March 19, 2014
Glasgow, UK: Women whose breast cancer has spread to just a few lymph nodes under their arm are less likely to have their disease recur or to die from it if they have radiotherapy after mastectomy, according to new research ...

Chemotherapy before or after surgery for high-risk bladder cancer improves survival, but is not routinely administered

April 14, 2014
Contrary to treatment guidelines for high-risk bladder cancer, chemotherapy before or after surgery is not commonly used in routine clinical practice. The findings are published early online in Cancer, a peer-reviewed journal ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.